Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Buprenorphine Patch for ASD
NCT06772324Phase 2Not yet recruiting
- Sponsor
- Peking University Sixth Hospital
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of v1003 in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Peking University Sixth Hospital. Primary endpoints: Social Responsiveness Scale at Day 57 and Autism Behavior Checklist at Day 57. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
v1003
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06772324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772324.